Open Access

Tongue squamous cell carcinoma producing both parathyroid hormone-related protein and granulocyte colony-stimulating factor: a case report and literature review

  • Naoki Kaneko1,
  • Shintaro Kawano1Email author,
  • Ryota Matsubara1,
  • Yuichi Goto1, 2,
  • Teppei Jinno1,
  • Yasuyuki Maruse1,
  • Taiki Sakamoto1,
  • Yuma Hashiguchi1,
  • Masakazu Iida1 and
  • Seiji Nakamura1
World Journal of Surgical Oncology201614:161

https://doi.org/10.1186/s12957-016-0918-1

Received: 24 November 2015

Accepted: 15 June 2016

Published: 17 June 2016

The Erratum to this article has been published in World Journal of Surgical Oncology 2016 14:187

Abstract

Background

Paraneoplastic syndrome generally results from tumor-derived hormones or peptides that cause metabolic derangements. Common metabolic conditions include hyponatremia, hypercalcemia, hypoglycemia, and Cushing’s syndrome. Herein, we report a very rare case of tongue carcinoma presenting with leukocytosis and hypercalcemia.

Case presentation

A 57-year-old man was admitted to our hospital with tongue squamous cell carcinoma (cT4aN0M0, stage IV). He underwent radical resection following preoperative chemoradiotherapy, but locoregional recurrence was detected 2 months after surgery. He presented with marked leukocytosis and hypercalcemia with elevated serum levels of granulocyte colony-stimulating factor (G-CSF) and parathyroid hormone-related protein (PTHrP). He was therefore managed with intravenous fluids, furosemide, prednisolone, elcatonin, and pamidronate. However, the patient died 1 month later of carcinomatous pleuritis following distant metastasis to the lung. Immunohistochemical analyses of the resected specimens revealed positive staining for PTHrP and G-CSF in the cancer cells.

Conclusions

In this case, it was considered that tumor-derived G-CSF and PTHrP caused leukocytosis and hypercalcemia.

Keywords

Squamous cell carcinoma Parathyroid hormone-related protein Granulocyte colony-stimulating factor

Background

Malignant tumors occasionally secrete hormonal factors that can cause some types of paraneoplastic symptoms [13]. Hypercalcemia is a relatively common paraneoplastic syndrome, and recent studies have demonstrated that parathyroid hormone-related protein (PTHrP) secreted by tumor cells can cause hypercalcemia in patients with malignant tumors [4, 5], while leukocytosis is a paraneoplastic syndrome caused by tumor-derived granulocyte colony-stimulating factor (G-CSF) [6]. However, the paraneoplastic production of both PTHrP and G-CSF by cancer cells is extremely rare. In this case report, we present a patient with tongue squamous cell carcinoma presenting with hypercalcemia and leukocytosis caused by tumor-derived PTHrP and G-CSF.

Case presentation

A 57-year-old man was referred to the Department of Oral and Maxillofacial Surgery, Kyushu University, with a chief complaint of a painful ulcerative lesion on the left lateral border of his tongue (Fig. 1a). Magnetic resonance imaging (MRI) revealed a tumorous mass occupying half of the tongue on the left side, extending to the lingual septum, and partially invading into the internal pterygoid muscle (Fig. 1b). No metastatic lymph nodes were found in the bilateral neck by palpation, ultrasonography, or computed tomography (CT). The patient had a medical history of diabetes mellitus. Pathological diagnosis of an incisional biopsy specimen indicated a moderately differentiated squamous cell carcinoma (SCC) (cT4aN0M0, stage IV). Planning CT was carried out followed by preoperative chemoradiotherapy including external beam irradiation to the primary tumor and neck in daily fractions of 2 Gy, five times weekly for 3 weeks, and oral administration of S-1 (120 mg/day) started 1 week prior to radiotherapy and continued throughout the radiotherapy period. One month after completing the preoperative chemoradiotherapy, the tumor was resected by subtotal glossectomy and segmental mandibulectomy under general anesthesia. Modified radical neck dissection and reconstruction using a rectus abdominis myocutaneous flap were performed simultaneously with tumor resection. Pathologically, four metastatic lymph nodes were identified: one in level I, one in level II, and two in level III. The histopathological response of the primary tumor to preoperative chemoradiotherapy was poor, and many residual carcinoma cells were noted in the muscular tissues in the resected specimens, though the surgical margin was tumor-free. Locoregional recurrence was detected by CT imaging 3 months after surgery, and the patient received further chemoradiotherapy (S-1, 120 mg/day; external beam irradiation in daily fractions of 2 Gy, five times weekly for 7 weeks). However, after completion of the chemoradiotherapy, the patient developed hypercalcemia (maximum serum calcium level, 16.3 mg/dL) and leukocytosis (maximum white blood cell count, 22.7 × 103/μL). The serum levels of PTHrP and G-CSF increased in parallel with progression of his hypercalcemia and leukocytosis (Figs. 2 and 3). Immunohistochemical staining revealed expression of PTHrP and G-CSF in the residual cancer cells (Fig. 4a, b). Interleukin (IL)-6 expression was also detected in the cancer cells (Fig. 4c). Based on these clinical and pathological findings, the patient was diagnosed with hypercalcemia and leukocytosis associated with malignancy. He was subsequently managed with intravenous fluids, furosemide, prednisolone, elcatonin, and pamidronate. However, an F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scan disclosed multiple metastatic regions, including the pelvis, lung, femur, adrenal gland, sternal bone, and inguinal nodes, and he progressed to respiratory failure and died of carcinomatous pleuritis 1 month later.
Fig. 1

Intraoral and MRI findings. a Tumorous mass with ulcerative lesion on the left lateral border of the tongue. b Contrast-enhanced MRI findings. White arrow indicates tumorous mass

Fig. 2

Time course of serum levels of calcium and PTHrP. Serum levels of calcium and PTHrP gradually increased in parallel after the completion of chemoradiotherapy for locoregional recurrence

Fig. 3

Time course of white blood cell count and serum G-CSF level. The number of white blood cells and G-CSF level gradually increased in parallel

Fig. 4

Immunohistochemical staining for PTHrP, G-CSF, and IL-6 in residual cancer cells. (×400). a PTHrP. b G-CSF. c IL-6

Conclusions

We present a very rare case of a patient with tongue squamous cell carcinoma presenting with hypercalcemia and leukocytosis. The serum levels of PTHrP and G-CFS were markedly elevated in the patient, in line with progression of his hypercalcemia and leukocytosis. Furthermore, immunohistological staining revealed PTHrP and G-CSF expression in the residual carcinoma cells. These findings suggested that hypercalcemia and leukocytosis in this patient were associated with tumor-derived PTHrP and G-CSF.

Yoneda et al. reported only five cases (2.2 %) presenting with both hypercalcemia and leukocytosis among 225 oral malignancies [7], though they did not demonstrate if the hypercalcemia and leukocytosis were caused by tumor-derived PTHrP and G-CSF. To the best of our knowledge, there have been only 13 recorded cases of head and neck tumors that produced both PTHrP and G-CSF, including the current case (Table 1) [816], in all of which patients presented with both hypercalcemia and leukocytosis. Pathologically, squamous cell carcinoma was the most frequent type of tumor (10 cases, 76.9 %), but only three cases of tongue squamous cell carcinoma have been reported [11, 12]. Furthermore, except for a patient with a benign ameloblastoma, 11 of the 12 previous cases had a poor prognosis. In the patient with hypopharyngeal carcinoma, the serum levels of both PTHrP and G-CSF were remarkably decreased after radical resection and the patient was rescued [16]. The present and previous findings thus suggest that increased serum levels of both PTHrP and G-CSF are indicative of a poor prognosis in patients with head and neck tumors.
Table 1

Case reports of head and neck tumors producing both PTHrP and G-CSF

No. [ref]

Sex

Age (year)

Primary site

Histological type

TNM classification

Differentiation

Serum Ca

Leukocyte (/μL)

Serum PTHrP (pmol/L) (normal range)

Serum G-CSF (pg/mL) (normal range)

Main metastases

Outcome

1 [8]

Female

65

Thyroid gland

Anaplastic carcinoma

13.8

142,000

4.02 (<1.1)

318 (<30)

Cervix, lung, liver

death

2 [9]

Male

48

Tonsil

SCC

11.4

62,100

533.3 (<55.3)

3450 (<30)

Cervix, lung, liver,

Death

3 [10]

Female

63

Thyroid gland

Follicular and papillary carcinoma

T2N1bM1

Well

13.4

34,700

3.9

196

Lung, bone

Death

4 [11]

Male

73

Buccal mucosa

SCC

T4N3M1

Poor

15.1

40,200

108.5 (<55.3)

1800 (<30)

Lung

Death

5 [11]

Male

60

Gingiva

SCC

T4N2M0

Well

18.1

15,800

227.9 (<55.3)

34.3 (<30)

Bone, lung

Death

6 [11]

Male

82

Tongue

SCC

T3N2M0

Poor

14.7

79,000

132 (<55.3)

274 (<30)

Lung

Death

7 [11]

Male

65

Buccal mucosa

SCC

T4N2M0

Poor

16.2

34,600

255 (<55.3)

211 (<30)

Lung, liver, pancreas

Death

8 [12]

Male

61

Tongue

SCC

T1N0MX

Well

28.5

31,300

3109 (<16) [pg/mL]

285 (<20) (pleural fluid)

Cervix, lung

Death

9 [13]

Male

65

Larynx

SCC

T4N3M0

18

60,000

5.6 (<0.5)

222 (<38)

Cervix, lung

Death

10 [14]

Female

57

Hypopharynx

SCC

T3N2bMX

Poor

14.2

46,300

12.4 (<1.1)

111 (<39)

Cervix, lung, liver, bone, kidney, skin

Death

11 [15]

Female

32

Mandible

Ameloblastoma

11.3

37,200

14.7 (<1.1)

68 (<30)

Survive

12 [16]

Male

76

Hypopharynx

SCC

T4aN2cM0

Moderate

11.2

20,230

3.1 (<1.1)

213 (<39)

Cervix, esophagus

Survive

Present case

Male

57

Tongue

SCC

T4aN0M0

Moderate

16.3

22,770

12.2 (<1.1)

60 (<39)

Cervix, lung, bone, femur, adrenal gland, groin

Death

Hypercalcemia can be categorized as humoral hypercalcemia of malignancy (HHM) or local osteolytic hypercalcemia (LOH) [17]. HHM is caused by tumor-derived PTHrP, while LOH is mainly caused by osteolysis associated with bone metastasis. The present patient demonstrated multiple bone metastases on FDG-PET with elevated serum PTHrP levels, suggesting the existence of both HHM and LOH in this case. The clinical manifestations of hypercalcemia affect the neuromuscular, renal, gastrointestinal, skeletal, and cardiovascular systems [18], and anti-hypercalcemic therapy should therefore be initiated as soon as possible to avoid hypercalcemic crisis [19]. In this patient, saline infusion (2000–3000 mL/day) with concomitant loop diuretics (furosemide) was administered to increase calcium excretion and reduce serum levels as rapidly as possible. We also administered calcitonin (a naturally occurring peptide hormone that inhibits bone resorption and increases renal calcium excretion) and a bisphosphonate (alendronate) to treat the hypercalcemia [20]. Bisphosphonates are effective therapeutic agents for hypercalcemia that inhibit osteoclast differentiation and function [21]. We also used prednisolone to reduce gastrointestinal calcium absorption [22]. However, although the patient’s calcium levels were normalized by this therapy, subsequent hypercalcemic exacerbation developed. Yamazaki et al. demonstrated an average survival period of 39.0 days from the diagnosis of hypercalcemia in patients with oral cancer treated with bisphosphonates or calcitonin, compared with 19.5 days in untreated patients [11]. These results suggest that the prognosis of patients with tumor-derived PTHrP and G-CSF is extremely unfavorable, though anti-hypercalcemic therapy may slightly improve life expectancy.

Numerous previous studies have shown that G-CSF is responsible for paraneoplastic leukocytosis [6, 7, 2325]. However, the mechanisms responsible for the production of these hormonal factors by tumor cells remain unknown. Recent studies have suggested that some inflammatory cytokines, including IL-6, may be associated with G-CSF production by malignant cells [26]. Moreover, hypercalcemia has been associated with cosecretion of PTHrP and IL-6 [27]. We previously showed that increased IL-6 expression in cancer cells predicted a poor response to chemoradiotherapy and an unfavorable prognosis in patients with oral SCC [28]. The current patient demonstrated a poor histological response to preoperative chemoradiotherapy and strong IL-6 expression in the residual cancer cells. These results suggested that IL-6 may play a key role in resistance to chemoradiotherapy and production of PTHrP and G-CSF in the cancer cells. However, further in vitro and in vivo studies are needed to clarify the association between IL-6 expression in oral squamous cell carcinoma and the production of PTHrP and G-CSF.

Abbreviations

FDG-PET, F-18 fluorodeoxyglucose positron emission tomography; G-CSF, granulocyte colony-stimulating factor; HHM, humoral hypercalcemia of malignancy; IL-6, interleukin 6; LOH, local osteolytic hypercalcemia; PTHrP, parathyroid hormone-related protein; SCC, squamous cell carcinoma

Notes

Declarations

Acknowledgements

We are very thankful to our patient for providing his informed consent for publication of this case report.

Funding

This work was supported by a Grant-in-Aid (26463014, 60615798, 26670869) from the Japanese Ministry of Education, Culture, Sports, Science and Technology.

Availability of data and materials

The authors do not wish to share their data. They respect the patient’s rights to privacy and to protect his identity. The authors presented all the necessary information about their case report in the manuscript. Raw data regarding our patient are managed strictly. However, about the literature review, all used literature is referenced appropriately in the “References” section.

Authors’ contributions

SK, MI, and SN contributed to the treatment of the patient. NK, YM, and TH collected the clinical data. RM, YG, and TJ prepared and analyzed the pathological data. NK and SK drafted the manuscript. RM, YG, TJ, YM, TS, TH, and SN helped in the manuscript drafting. All authors have read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.

Ethics approval and consent to participate

This report was approved by the Ethics Committee of Kyushu University, and written informed consent was obtained from all of the patients (IRB serial number: 27-362).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University
(2)
Maxillofacial Diagnostic and Surgical Science, Department of Oral and Maxillofacial Rehabilitation, Course for Developmental Therapeutics, Kagoshima University Graduate School of Medical and Dental Sciences

References

  1. Robinson WA. Granulocytosis in neoplasia. Ann NY Acad Sci. 1974;230:212–8.View ArticlePubMedGoogle Scholar
  2. Broadus AE, Mangin M, Ikeda K, Insogna KL, Weir EC, Burtis WJ, et al. Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. N Engl J Med. 1988;319:556–63.View ArticlePubMedGoogle Scholar
  3. Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab. 2006;91:371–7.View ArticlePubMedGoogle Scholar
  4. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Jagger H, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science. 1987;237:893–6.View ArticlePubMedGoogle Scholar
  5. Mangin M, Ikeda K, Dreyer BE, Broadus AE. Isolation and characterization of the human parathyroid hormone-like peptide gene. Proc Natl Acad Sci U S A. 1989;86:2408–12.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Asano S, Urabe A, Okabe T, Sato N, Kondo Y. Demonstration of granulopoietic factor(s) in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissue. Blood. 1977;49:845–52.PubMedGoogle Scholar
  7. Yoneda T, Nishimura R, Kato I, Masatoshi O, Masaaki T, Masayoshi S. Frequency of the hypercalcemia-leukocytosis syndrome in oral malignancy. Cancer. 1991;68:617–22.View ArticlePubMedGoogle Scholar
  8. Yazawa S, Toshimori H, Nakatsuru K, Katakami H, Takemura J, Matsukura S. Thyroid anaplastic carcinoma producing granulocyte-colony-stimulating factor and parathyroid hormone-related protein. Intern Med. 1995;34:584–8.View ArticlePubMedGoogle Scholar
  9. Murao T, Takaba S, Fujita T. A case of squamous cell carcinoma of the tonsil with high concentration of serum granulocyte colony stimulating factor and parathyroid hormone-related protein. J Okayama Surg Pathol Assoc. 1997;34:9–12.Google Scholar
  10. Kunisue H, Tanaka K, Sonoo H, Kurebayashi J, Shimozuma K, Mikami Y. Transformation to undifferentiated from differentiated thyroid cancer associated with remarkable leukocytosis and hypercalcemia: report of a case. J Japanese Surg Assoc. 2000;61:886–9.View ArticleGoogle Scholar
  11. Yamazaki H, Ota Y, Karakida K, Sekiya R, Mizusawa N, GOTO J. Hypercalcemia in patients with oral cancer. Japan Soc Head Neck Cancer. 2000;26:95–100.View ArticleGoogle Scholar
  12. Obara S, Yoshimura Y. A case of tongue carcinoma showing leukocytosis and hypercalcemia with the production of G-CSF and PTHrP. Jpn J Oral Maxillofac Surg. 2001;47:22–4.View ArticleGoogle Scholar
  13. Tanaka K, Nibu K. Laryngeal squamous cell carcinoma with ectopic production of granulocyte colony-stimulating factor and parathyroid hormone-related protein. Int J Clin Oncol. 2005;10:195–7.View ArticlePubMedGoogle Scholar
  14. Tamura K, Yoshinaga T, Tanino M, Kimura T, Yamada N, Nishimura M, et al. Hypopharyngeal squamous cell carcinoma producing both granulocyte colony-stimulating factor and parathyroid hormone-related protein. Pathol Int. 2008;58:652–6.View ArticlePubMedGoogle Scholar
  15. Ota Y, Aoki T, Otsuru M, Hirabayashi K, Nakamura N, Tsukinoki K. Huge ameloblastoma associated with hypercalcemia, leukocytosis, and elevated tumor markers via production of parathyroid hormone-related protein and granulocyte colony-stimulating factor. J Oral Maxillofac Surg. 2011;70:1380–5.View ArticlePubMedGoogle Scholar
  16. Matsuo M, Rikimaru F, Higaki Y, Masuda M. A case of G-CSF producing hypopharyngeal carcinoma. Japanese J Head Neck Cancer. 2013;39:60–5.Google Scholar
  17. Rosol TJ, Capen CC. Biology of disease: mechanisms of cancer-induced hypercalcemia. Lab Invest. 1992;67:680–702.PubMedGoogle Scholar
  18. Bajorunas DR. Clinical manifestations of cancer-related hypercalcemia. Semin Oncol. 1990;17:16–25.PubMedGoogle Scholar
  19. Iwase M, Takemi T, Manabe M, Nagumo M. Hypercalcemic complication in patients with oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2003;32:174–80.View ArticlePubMedGoogle Scholar
  20. Hosking DJ, Gilson D. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcemia of malignancy. Q J Med. 1984;211:359–68.Google Scholar
  21. Watters J, Gerrard G, Dodwell D. The management of malignant hypercalcemia. Drugs. 1996;52:837–48.View ArticlePubMedGoogle Scholar
  22. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85:838–54.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Horii A, Shimamura K, Honjo Y, Mitani K, Miki T, Takashima S, et al. Granulocyte colony stimulating factor-producing tongue carcinoma. Head Neck. 1997;19:351–6.View ArticlePubMedGoogle Scholar
  24. Ito T, Shimamura K, Shoji K, Akatsuka A, Kiryu Y, Tamaoki N, et al. Urinary bladder carcinoma producing granulocyte colony stimulating factor (G-CSF): a case report with immunohistochemistry. Virchows Archiv A Pathol Anat. 1993;422:487–90.View ArticleGoogle Scholar
  25. Ota S, Kato A, Kobayashi H, Yonezumi M, Yamaguchi J, Musashi M, et al. Monoclonal origin of an esophageal carcinosarcoma producing granulocyte-colony stimulating factor. Cancer. 1998;82:2102–11.View ArticlePubMedGoogle Scholar
  26. Inoue M, Minami M, Fujii Y, Matsuda H, Shirakura R, Kido T. Granulocyte colony-stimulating factor and interleukin-6-producing lung cancer cell line. LCAM J Surg Oncol. 1997;64:347–50.View ArticlePubMedGoogle Scholar
  27. Asanuma N, Hagiwara K, Matsumoto I, Matsuda M, Nakamura F, Kouhara H, et al. PTHrP-producing tumor: squamous cell carcinoma of the liver accompanied by humoral hypercalcemia of malignancy, increased IL-6 and leukocytosis. Intern Med. 2002;41:371–6.View ArticlePubMedGoogle Scholar
  28. Jinno T, Kawano S, Maruse Y, Matsubara R, Goto Y, Sakamoto T, et al. Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma. Oncol Rep. 2015;33:2161–8.PubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement